GlassScriptPhysician profile
Matthew Merle Holcomb
NPI 1033406855
$4,195.72
in general payments reported to CMS, 2019-2025
27 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $700 · 2022: $1,164 · 2023: $689 · 2024: $641 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $635.93 | 2021-2025 | Myrbetriq, Xtandi |
| Dendreon Pharmaceuticals LLC | $504.16 | 2021-2025 | Provenge |
| Janssen Biotech, INC. | $447.05 | 2021-2025 | Erleada |
| Sumitomo Pharma America, INC. | $406.59 | 2023-2025 | Gemtesa |
| Abbvie INC. | $398.53 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $257.07 | 2021-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $186.42 | 2022-2024 | Lynparza, Welireg, Keytruda |
| Urogen Pharma, INC. | $184.02 | 2022-2024 | Jelmyto |
| Procept Biorobotics Corporation | $159.99 | 2025 | |
| Pfizer INC. | $146.91 | 2021-2025 | |
| Urovant Sciences INC | $101.37 | 2021-2022 | |
| Accord Healthcare, INC. | $99.92 | 2025 | |
| Amgen INC. | $92.96 | 2021-2023 | Xgeva |
| Blue Earth Diagnostics | $80.22 | 2021-2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $74.27 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $71.75 | 2021-2025 | Barrigel, Urolift |
| Tolmar Pharmaceuticals, INC. | $63.31 | 2021-2022 | |
| 180 Medical, INC. | $61.30 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.72 | 2022-2025 | |
| Antares Pharma, INC. | $41.27 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $29.29 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $19.10 | 2022 | |
| Coloplast Corp | $18.64 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.86 | 2021 | |
| Tolmar, INC. | $14.07 | 2023 | |
| Cycle Pharmaceuticals INC | $13.75 | 2025 | Venxxiva |
| Myovant Sciences INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.